For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

(Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) For those who are overweight or obese, medications known as glucagon-like peptide-1 agonists, or GLP-1s, have become very ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

Insurers and self-funded employers are making significant changes to their GLP-1 drug coverage policies in 2025, reflecting the financial and operational challenges posed by the high-cost medications.

Between Novo Nordisk's (NVO) slightly disappointing results for its latest GLP-1 candidate, CagriSema, and questions that remain about Amgen's (AMGN) highly anticipated once-monthly injectable ...

GLP-1 weight-loss drugs have dominated healthcare headlines in 2024, marked by expanded employer coverage, dynamic pricing changes, and pharmaceutical giants like Novo Nordisk (NVO) and Eli Lilly ...

Originally designed for people with diabetes, GLP-1 medications like Ozempic and Wegovy help stabilize blood sugar and reduce appetite. They also tend to quiet “food noise,” or constant ...